Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Dr. Reddy's Laboratories Ltd (RDY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,060,721
  • Shares Outstanding, K 165,820
  • Annual Sales, $ 2,171 M
  • Annual Income, $ 186,000 K
  • 36-Month Beta 0.39
  • Price/Sales 2.79
  • Price/Cash Flow 16.82
  • Price/Book 3.25

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.89 +9.80%
on 12/11/17
37.56 -0.93%
on 12/15/17
+1.27 (+3.53%)
since 11/15/17
3-Month
33.89 +9.80%
on 12/11/17
38.27 -2.77%
on 09/21/17
+3.43 (+10.15%)
since 09/15/17
52-Week
29.83 +24.74%
on 08/21/17
46.95 -20.75%
on 02/03/17
-8.71 (-18.97%)
since 12/15/16

Most Recent Stories

More News
Dr. Reddy's Announces Approval of Impoyz(TM) (clobetasol propionate) Cream, 0.025% First-Cycle NDA Approval

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), through its wholly owned subsidiary Promius Pharma, LLC, today announced its fifth consecutive, first-cycle NDA approval...

RDY : 37.21 (+1.81%)
Dr. Reddy's Laboratories Announces the Launch of Clofarabine Injection in the U.S. Market

Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Clofarabine Injection, a therapeutic equivalent generic version of Clolar(R) (clofarabine)...

RDY : 37.21 (+1.81%)
VIVUS (VVUS) Q3 Loss Narrows, Qsymia Falters, Shares Down

VIVUS (VVUS) reported third-quarter results wherein it reported narrower-than- expected loss. However, Qsymia sales fell from the year-ago period.

VVUS : 0.53 (-3.64%)
RDY : 37.21 (+1.81%)
EXEL : 26.10 (+0.58%)
TEVA : 18.61 (+7.57%)
Dr. Reddy's Laboratories Announces the Launch of Generic Azacitidine for Injection in the Canadian Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) is pleased to announce that generic Azacitidine for injection 100 mg/vial, a bioequivalent generic version of VIDAZA(R)...

RDY : 37.21 (+1.81%)
Dr. Reddy's (RDY) Q2 Earnings and Revenues Decline Y/Y

Dr. Reddy's (RDY) earnings declined year over year but revenues increased on a year-over-year basis. The company remains focused on launching new products.

AGEN : 3.56 (+1.14%)
LGND : 135.87 (-0.12%)
RDY : 37.21 (+1.81%)
ADAP : 7.37 (unch)
Dr. Reddy's Laboratories Ltd. Sponsored ADR to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / October 31, 2017 / Dr. Reddy's Laboratories Ltd. Sponsored ADR (NYSE: RDY) will be discussing their earnings results in their Q2 Earnings Call to be held on October 31, 2017...

RDY : 37.21 (+1.81%)
Dr. Reddy's Q2 and H1 FY18 Financial Results

--Q2 EBITDA at Rs. 6.9 Bn[19.4% of Revenues]

RDY : 37.21 (+1.81%)
Lifshitz & Miller LLP Announces Investigation of Antares Pharma, Inc., CenturyLink, Inc., CytRx Corporation, Dentsply Sirona, Inc., Dr. Reddy's Laboratories Limited, J.Jill, Inc., and Navient Corporation

Antares Pharma, Inc. (ATRS)

NAVI : 13.20 (+4.60%)
RDY : 37.21 (+1.81%)
ATRS : 2.01 (+4.15%)
CTL : 16.99 (+3.16%)
CYTR : 1.75 (unch)
XRAY : 66.48 (+1.26%)
JILL : 7.46 (+5.82%)
DEADLINE TODAY: Lundin Law PC Announces Securities Class Action Lawsuit against Dr. Reddy's Laboratories Limited and Reminds Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / October 24, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE:...

RDY : 37.21 (+1.81%)
FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Dr. Reddy's Laboratories Ltd. (RDY) & Lead Plaintiff Deadline: October 24, 2017

NEW YORK, NY / ACCESSWIRE / October 24, 2017 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Dr. Reddy's Laboratories Ltd. ("Dr. Reddy's" or the...

RDY : 37.21 (+1.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy and ranks in the Top 1% of all short term signal directions.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Doctor Reddy's is an emerging global pharmaceutical company with proven research capabilities. They are vertically integrated with a presence across the pharmaceutical value chain. They produce finished dosage forms, active pharmaceutical ingredients and biotechnology products and market them globally,...

See More

Key Turning Points

2nd Resistance Point 38.12
1st Resistance Point 37.66
Last Price 37.21
1st Support Level 36.65
2nd Support Level 36.10

See More

52-Week High 46.95
Fibonacci 61.8% 40.41
Fibonacci 50% 38.39
Last Price 37.21
Fibonacci 38.2% 36.37
52-Week Low 29.83

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.